Strategic Partnership Will Advance Development of a Novel Bispecific
Immuno-Oncology Antibody Targeting Compelling Biological Pathway
Implicated in Multiple Solid Tumor Indications
Focuses on New Mechanism of Action of Tumor Targeting Demonstrating
the Versatility of Alligator’s Antibody Discovery Platform ALLIGATOR-GOLD®
and Aptevo’s ADAPTIR™ Protein Therapeutic Platform
SEATTLE and LUND, Sweden, July 20, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a
biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience (Nasdaq
Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today
announced that they have entered into an agreement to co-develop a novel immunotherapy bispecific antibody candidate, ALG.APV-527,
based on Alligator’s first generation bispecific antibody, ATOR-1016. The new bispecific candidate was developed using
Aptevo’s bispecific technology platform and includes proprietary binding elements generated by Alligator’s
ALLIGATOR-GOLD® antibody library. Initiation of cell line development for the manufacturing of clinical material
is expected to begin shortly.
Working under a previously executed material transfer agreement, the companies have engineered and selected
ALG.APV-527 as a lead bispecific antibody candidate, featuring a novel mechanism of action targeting 4-1BB, a member of the TNFR
superfamily of co-stimulatory receptors found on activated T cells, and an undisclosed tumor antigen widely overexpressed in a
number of different types of cancer.
Under the terms of the agreement, the parties will jointly own and share equally in the development costs
associated with advancing this candidate through to the end of Phase 2 clinical development. At that time, the parties may
opt to out-license the candidate or continue further development separately or in partnership. In addition, the agreement
provides an option for the companies to develop a second bispecific antibody candidate based on this novel mechanism of action,
which would also be jointly owned and funded by Aptevo and Alligator.
The co-stimulatory receptor 4-1BB is known to play an important role in modulating and augmenting the immune
response to cancer by promoting the activation, expansion and enhanced effector function of tumor-specific T cells. It is,
therefore, an especially promising target for new immunotherapeutic approaches for cancer treatment. If successfully
developed, this new bispecific antibody candidate could have utility in the potential treatment of a broad spectrum of cancers
including breast, cervical, non-small-cell-lung, prostate, renal, gastric, colorectal and bladder cancers. While this tumor
antigen is widely expressed in multiple types of solid tumors, it shows limited expression on normal tissues, suggesting the
potential for tumor-directed immunotherapy with improved efficacy and fewer side effects.
“Our collaboration with Alligator Bioscience has unlocked tremendous synergies, enabling us to capitalize on our
companies’ respective expertise in therapeutic antibody engineering,” said Marvin L. White, President and Chief Executive Officer
of Aptevo. “The addition of a 4-1BB bispecific candidate expands and diversifies Aptevo’s portfolio while demonstrating the
flexibility of our ADAPTIR platform in addressing novel mechanisms of action, in addition to redirected T-cell cytotoxicity.
Also, importantly, it allows us to pursue an exciting new therapeutic opportunity with broad potential application in the treatment
of non-hematological cancers. If proven successful, this new approach would be a significant advance in cancer
immunotherapy. We’re extremely pleased to collaborate with Alligator Bioscience in the development of novel tumor-targeting
bispecific antibody therapies.”
“With five immuno-oncology programs currently in development, each with first- or best-in-class potential, this
partnership with Aptevo allows us to further build on the promise of bispecific therapeutics for tumor-directed immunotherapy,”
said Per Norlén, Chief Executive Officer of Alligator Bioscience. “Our technology platform enables the generation of highly
functional antibodies with optimal stability and manufacturing properties, merged into an exceptional bispecific antibody using
Aptevo´s ADAPTIR platform. We look forward to advancing our collaboration with Aptevo on this promising new therapeutic
approach.”
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to
meaningfully improve patients’ lives. Our core technology is the ADAPTIR modular protein technology platform. Aptevo has four
commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates
in immuno-oncology.
About Alligator Bioscience
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology
antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical product candidates (ADC-1013, ATOR-1015,
ATOR-1017, and ALG.APV-527) and novel research candidates. ADC-1013 is licensed to Janssen Biotech, Inc., part of J&J, for
development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund,
Sweden, and has approximately 45 employees. For more information, please visit www.alligatorbioscience.se.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo’s outlook,
financial performance or financial condition, our technology and related pipeline, collaboration and partnership opportunities,
commercial portfolio, Aptevo’s future growth rates, Aptevo’s ability to timely manufacture its products, and any other statements
containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar
expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and
expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should
realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ
materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking
statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo
does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause our actual results to differ materially from those
indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial
results as a result of the separation; a deterioration in our business or prospects; the ability of our contractors and suppliers
to supply product and materials; our ability and the ability of our contractors and suppliers to maintain compliance with
cGMP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets
and our ability to retain patients; adverse developments in the U.S. or global capital markets, credit markets or economies
generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set
forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Annual Report on Form 10-K, as
filed on March 15, 2017, and our subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many,
but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.
For Further Information: Aptevo Therapeutics Stacey Jurchison, Sr. Director, Investor Relations and Corporate Communications 206-859-6628 JurchisonS@apvo.com Alligator Bioscience Per Norlén, CEO E-mail: per.norlen@alligatorbioscience.com Rein Piir VP, Investor Relations +46 708 537292 rein.piir@alligatorbioscience.com